Long-term follow-up of premature infants treated with prophylactic, intratracheal recombinant human CuZn superoxide dismutase

被引：23

作者：

Davis J.M. ^{[1
,9
]}

Richter S.E. ^{[1
]}

Biswas S. ^{[1
]}

Rosenfeld W.N. ^{[1
]}

Parton L. ^{[2
]}

Gewolb I.H. ^{[3
]}

Parad R. ^{[4
]}

Carlo W. ^{[5
]}

Couser R.J. ^{[6
]}

Baumgart S. ^{[7
]}

Atluru V. ^{[1
]}

Salerno L. ^{[8
]}

Kassem N. ^{[8
]}

机构：

[1] Department of Pediatrics, Winthrop University Hospital, Mineola, NY

[2] University Hospital, Stony Brook, NY

[3] University of Maryland, Medical Center, Baltimore, MD

[4] Brigham and Women's Hospital, Boston, MA

[5] University of Alabama, Medical Center, Birmingham, AL

[6] Children's Healthcare, Minneapolis, MN

[7] Thomas Jefferson University, Philadelphia, PA

[8] Bio-Technology General Corporation, Iselin, NJ

[9] Department of Pediatrics, Winthrop University Hospital, Mineola, NY 11501

来源：

Journal of Perinatology | 2000年 / 20卷 / 4期

关键词：

D O I：

10.1038/sj.jp.7200363

中图分类号：

学科分类号：

摘要：

OBJECTIVE: To examine the long-term effects of treatment with recombinant human CuZn superoxide dismutase (rhSOD) in infants enrolled previously in two placebo-controlled trials. STUDY DESIGN: Records for 46 (88%) infants were examined, with 19 infants having received either single or multiple intratracheal (i.t.) doses of placebo, 12 having received a single i.t. dose of rhSOD, and 15 having received multiple i.t. doses of rhSOD. Mean age at follow-up was 28 months corrected age. Records were examined for neurologic dysfunction, developmental delay, and any significant medical disorders. RESULTS: Four placebo infants (21%) had evidence of neurodevelopmental abnormalities and four infants developed asthma. Four single-dose rhSOD infants (33%) had neurodevelopmental abnormalities and two infants developed asthma. One multiple-dose rhSOD infant had evidence of neurodevelopmental abnormalities and one developed asthma. No other differences were found between the placebo and rhSOD groups. CONCLUSION: Preliminary data suggest that rhSOD is safe and not associated with any long-term adverse effects. Further results will depend on the results of multicenter trials of rhSOD in preterm infants.

引用

页码：213 / 216

页数：3

共 17 条

[1]

Davis J.M., Rosenfeld W.N., Chronic lung disease, Neonatology, pp. 453-477, (1994)

[2]

Singer L., Yamashita T., Lilien L., Collin M., Baley J., A longitudinal study of developmental outcome of infants with bronchopulmonary dysplasia and very low birth weight, Pediatrics, 100, pp. 987-993, (1997)

[3]

Volpe J.J., Brain injury in the premature infant: From pathogenesis to prevention, Brain Dev, 19, pp. 519-534, (1997)

[4]

Davis J.M., Rosenfeld W.N., Sanders R.J., Gonenne A., Prophylactic effects of recombinant human superoxide dismutase in neonatal lung injury, J Appl Physiol, 74, pp. 2234-2241, (1993)

[5]

Turrens J.F., Crapo J.D., Freeman B.A., Protection against oxygen toxicity by intravenous injection of liposome-entrapped catalase and superoxide dismutase, J Clin Invest, 73, pp. 87-95, (1984)

[6]

Padmanabhan R.V., Gudapaty R., Liener J.E., Schwartz B.A., Hoidal J.R., Protection against oxygen toxicity by the intratracheal administration of liposome-encapsulated superoxide dismutase or catalase, Am Rev Respir Dis, 132, pp. 164-167, (1985)

[7]

Ment L.R., Stewart W.B., Duncan C.C., Beagle puppy model of intravenuicular hemorrhage, J Neurosurg, 62, pp. 563-569, (1985)

[8]

Rosenfeld W.N., Davis J.M., Parton L., Et al., Safety and pharmacokinetics of recombinant human superoxide dismutase administered intratracheally to premature neonates with respiratory distress syndrome, Pediatrics, 97, pp. 811-817, (1996)

[9]

Davis J.M., Rosenfeld W.N., Richter S.E., Et al., Safety and pharmacokinetics of multiple doses of recombinant human superoxide dismutase administered intratracheally to premature neonates with respiratory distress syndrome, Pediatrics, 100, pp. 24-30, (1997)

[10]

Palta M., Sadek M., Barnet J.H., Et al., Evaluation of criteria for chronic lung disease in surviving very low birth weight infants, J Pediatr, 132, pp. 57-63, (1998)

← 1 2 →